GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » PS Ratio

MindBio Therapeutics (XCNQ:MBIO) PS Ratio : 11.25 (As of Jun. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, MindBio Therapeutics's share price is C$0.045. MindBio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00. Hence, MindBio Therapeutics's PS Ratio for today is 11.25.

Good Sign:

MindBio Therapeutics Corp stock PS Ratio (=11.25) is close to 1-year low of 11.25

The historical rank and industry rank for MindBio Therapeutics's PS Ratio or its related term are showing as below:

XCNQ:MBIO' s PS Ratio Range Over the Past 10 Years
Min: 11.25   Med: 25   Max: 70
Current: 11.25

During the past 3 years, MindBio Therapeutics's highest PS Ratio was 70.00. The lowest was 11.25. And the median was 25.00.

XCNQ:MBIO's PS Ratio is ranked worse than
55.34% of 1001 companies
in the Biotechnology industry
Industry Median: 9.48 vs XCNQ:MBIO: 11.25

MindBio Therapeutics's Revenue per Sharefor the three months ended in Mar. 2024 was C$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00.

Back to Basics: PS Ratio


MindBio Therapeutics PS Ratio Historical Data

The historical data trend for MindBio Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics PS Ratio Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
PS Ratio
- - -

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 13.75

Competitive Comparison of MindBio Therapeutics's PS Ratio

For the Biotechnology subindustry, MindBio Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindBio Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's PS Ratio falls into.



MindBio Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

MindBio Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.045/0.004
=11.25

MindBio Therapeutics's Share Price of today is C$0.045.
MindBio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


MindBio Therapeutics  (XCNQ:MBIO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


MindBio Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus